During Michaelmas Term, OxTalks will be moving to a new platform (full details are available on the Staff Gateway).
For now, continue using the current page and event submission process (freeze period dates to be advised).
If you have any questions, please contact halo@digital.ox.ac.uk
Vorinostat is currently being evaluated in clinical trials in a shock and kill approach to cure HIV. Transcriptomic and proteomic profiling of Vorinostat in primary CD4 T cells has identified noteworthy off-target effects, subject-to-subject variation, as well as biomarkers that may be monitored to confirm compound exposure.
